Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
Belite Bio announced that data regarding its Phase 3 Dragon Study of Tinlarebant for Stargardt disease will be presented at two upcoming medical conferences. Presentations are scheduled for the SOG Annual Congress in Lausanne, Switzerland, on August 27, and the APVRS Congress in Gold Coast, Australia, on August 29-30.
Key figures
- Drug Name
- Tinlarebant
- Phase Of Trial
- Phase 3
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.